In HCC cell lines under NASH-like conditions, tipifarnib suppressed protein expression of NF-κB and TGF-β, which are associated with inflammation and fibrosis [39,40,41]. Here, TGFB1 is linked to metabolic dysfunction-associated steatohepatitis.